Fasgen, Inc.

5210 Eastern Avenue
Baltimore, MD 21201
http://fasgen.com
5 Employees

SBIR Award Summary

Total Number of Awards 20
Total Value of Awards $8.71MM
First Award Date 12/10/01
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Medghalchi Dr. Susan Medghalchi 2 Message
Owens Albert H. Owens 14
Medghalchi Susan Medghalchi 4

20 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): The morbidity of obesity is a direct result of excess triglyceride accumulation, predominantly in adipose tissue and liver. Particularly in the liver, steatosis contributes to insulin resistance and Type II diabetes, and non- alcoholic steatohepatitis (NASH), which may progress to cirrhosis and liver failure....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/30/09 - 08/31/10

DESCRIPTION (provided by applicant): The morbidity of obesity is a direct result of excess triglyceride accumulation, predominantly in adipose tissue and liver. Particularly in the liver, steatosis contributes to insulin resistance and Type II diabetes, and non- alcoholic steatohepatitis (NASH), which may progress to cirrhosis and liver failure....

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-07-08
Budget: 05/01/08 - 04/30/10

DESCRIPTION (provided by applicant): During the last decade, increasing interest has developed in fatty acid synthase (FAS) as a potential diagnostic and therapeutic target for human cancer. These notions are based on two fundamental observations: [1] FAS is highly expressed in most common human cancers, and [2] pharmacological inhibition of FAS...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/07 - 08/31/09

DESCRIPTION (provided by applicant): During the period of support provided by Phase I of SBIR-AT-NIDDK, 50 compounds were evaluated as a basis for drug development. The most promising of these compounds have been evaluated in a series of carefully integrated in-vitro experiments using informative cell lines and in-vivo studies in lean and diet ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-07-08
Budget: 05/01/07 - 04/30/08

DESCRIPTION (provided by applicant): During the last decade, increasing interest has developed in fatty acid synthase (FAS) as a potential diagnostic and therapeutic target for human cancer. These notions are based on two fundamental observations: [1] FAS is highly expressed in most common human cancers, and [2] pharmacological inhibition of FAS...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 04/01/07 - 03/31/09

DESCRIPTION (provided by applicant): Phase I Ovarian cancer is the fifth leading cause of cancer death among U.S. women and has the highest mortality rate of all gynecologic cancers, with 23,400 new cases and 13,900 deaths projected in 2001. Screening markers and therapies remain limited, and 5-year survival rates for the 60% of women diagnos...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/06 - 08/31/07

DESCRIPTION (provided by applicant): During the period of support provided by Phase I of SBIR-AT-NIDDK, 50 compounds were evaluated as a basis for drug development. The most promising of these compounds have been evaluated in a series of carefully integrated in-vitro experiments using informative cell lines and in-vivo studies in lean and diet ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 05/01/06 - 10/31/06

DESCRIPTION (provided by applicant): Tuberculosis poses a major global public health problem. Nearly one-third of the world's population (approximately 2 billion people) harbors latent TB infections. An estimated 8 million cases of active TB are diagnosed annually and approximately 2 million people die of the disease. Additionally, the pandemic...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 04/04/06 - 03/31/07

DESCRIPTION (provided by applicant): Phase I Ovarian cancer is the fifth leading cause of cancer death among U.S. women and has the highest mortality rate of all gynecologic cancers, with 23,400 new cases and 13,900 deaths projected in 2001. Screening markers and therapies remain limited, and 5-year survival rates for the 60% of women diagnos...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/05 - 08/31/06

DESCRIPTION (provided by applicant): During the period of support provided by Phase I of SBIR-AT-NIDDK, 50 compounds were evaluated as a basis for drug development. The most promising of these compounds have been evaluated in a series of carefully integrated in-vitro experiments using informative cell lines and in-vivo studies in lean and diet ...

Load More